



Every drug can be made and every disease can be treated

## About WuXi AppTec

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated." Please visit: <http://www.wuxiapptec.com>

## Platform and Services

WuXi AppTec is a full-service provider of open-access capabilities and technology that enables customers worldwide to advance discoveries in the health sciences and deliver treatment to those in need. Our services include:

- + **Chemistry Platform (WuXi Chemistry)**  
Integrated, end-to-end chemistry research, development, and commercial manufacturing services.
- + **Biology Discovery Platform (WuXi Biology)**  
A full spectrum of biology-related services to support drug discovery and development.
- + **Testing Services Platform (WuXi Testing)**  
Seamless drug and medical device testing services from preclinical testing to clinical trials.
- + **Cell and Gene Therapy CTDMO Platform (WuXi ATU)**  
Accelerates and transforms discovery, development, testing, manufacturing, and commercialization of cell and gene therapies.
- + **Domestic Discovery Platform (WuXi DDSU)**  
Provides drug discovery services to pharmaceutical and biotech customers operating in China.

## By the Numbers



More than

**41,000** employees worldwide



**32** in **9**  
facilities countries



**1,000,000+**  
square meters of laboratories, manufacturing sites and offices



**6,000+**  
customers including biotech and pharmaceutical companies, research institutions, scientists and entrepreneurs

\*Statistics updated as of September 30, 2023

## Advances in Medicine for Patients



WuXi AppTec's platform is used by more than 6,000 innovative customers, including biotech and pharmaceutical companies, research institutions, researchers, scientists and entrepreneurs in more than 30 countries to transform healthcare and medicine. Some of these successes include:

- + Advanced development of therapy approved by the U.S. Food and Drug Administration (FDA) and the China National Medical Products Administration (NMPA) for the treatment of adult patients with chronic hepatitis C virus genotypes 1 and 4 infections
- + Advanced development of first oral-targeted therapy approved by FDA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation
- + Supported the development of the first oral therapy approved by FDA and NMPA for the treatment of patients with chronic lymphocytic leukemia, mantle cell lymphoma and Waldenström's macroglobulinemia
- + Supported the acquisition of implied license of clinical trial from FDA for a small molecule drug for the treatment of Alzheimer's Disease
- + Provided all-round support for a BTK inhibitor to receive accelerated NDA approval for treatment of mantle cell lymphoma from FDA
- + Expedited a New Drug Application (NDA) submission to receive FDA approval for a breakthrough treatment of ovarian cancer

## Maintaining the Highest Global Standards

WuXi AppTec is devoted to safeguarding customers' data and intellectual property. A robust system of corporate governance ensures that information is protected and used in accordance with guidelines laid out by our customers and global privacy and healthcare policies.

WuXi AppTec adheres to global regulatory standards across all our business units, and has received regulatory approvals from agencies in Australia, Canada, China, the European Union, Japan, New Zealand, Switzerland and the United States.

